Literature DB >> 15001275

The robustness of dose distributions to displacement and migration of 125I permanent seed implants over a wide range of seed number, activity, and designs.

Luc Beaulieu1, Louis Archambault, Sylviane Aubin, E Oral, Richard Taschereau, Jean Pouliot.   

Abstract

PURPOSE: To investigate the robustness of permanent prostate implant dosimetry for various (125)I seed activities and various seed models. The dosimetric impact of seed misplacement and seed migration (seed loss) is also taken into account using various standard dose indices. METHODS AND MATERIALS: A dose-based inverse planning algorithm is used for automated dosimetric plan creation (45-60 s per plan) and provides an unbiased way to compare the robustness of various optimal dosimetric plans. Seed misplacement and seed migration are simulated by way of Monte Carlo, based on the measured displacement distributions from clinical postimplant cases. Plans were generated for seed activities between 0.2 and 1.4 mCi (0.25 to 1.78 U) and for 11 different seed models.
RESULTS: The numbers of seeds and needles are shown to decrease rapidly for a seed activity between 0.3 mCi and 0.6 mCi (0.38 and 0.76 U). The loss in V100, from 100%, because of seed misplacement is below 10% for an apparent activity ranging from 0.2 to 0.9 mCi (0.25 to 1.14 U). A minimum degradation in V100 is observed around 0.6-0.7 mCi (0.76-0.89 U). D90 increases from 150 to 170 Gy between 0.3 and 0.7 mCi (0.38 and 0.89 U) and decreases afterward to fall below 140 Gy at higher activity. V200 and D10 to the target volume both show an increase in hot spots up to 0.7 mCi, and then decrease linearly at higher activities for all seed models. V200 and D10 to the urethra remain about constant for all seed activities up to 0.8 mCi (1.02 U), at which point they start to decrease. All seed models follow this general trend.
CONCLUSIONS: Plans were shown to be robust to misplacement and migration of seeds over a wide range of seed activity and for various seed models. With a properly tuned inverse planning algorithm able to ensure the dose coverage and protection for the organs at risk in the presence of placement errors (displacement and migration), the choice of a preferred seed activity, in a range up to about 0.7 mCi (0.89 U), is open. The upper part of this range offers the opportunity to significantly reduce the number of seeds and needles, thus reducing surgical trauma to the patient, saving time in an operating room planning setting, and reducing the cost of a permanent prostate implant procedure.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15001275     DOI: 10.1016/j.ijrobp.2003.11.016

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Magnetic resonance imaging compatible robotic system for fully automated brachytherapy seed placement.

Authors:  Michael Muntener; Alexandru Patriciu; Doru Petrisor; Dumitru Mazilu; Herman Bagga; Louis Kavoussi; Kevin Cleary; Dan Stoianovici
Journal:  Urology       Date:  2006-12       Impact factor: 2.649

2.  Seed loss in prostate brachytherapy : Operator dependency and impact on dosimetry.

Authors:  Nancy El-Bared; Natanel Sebbag; Dominic Béliveau-Nadeau; Yannick Hervieux; Renée Larouche; Daniel Taussky; Guila Delouya
Journal:  Strahlenther Onkol       Date:  2016-02-29       Impact factor: 3.621

3.  Investigating the dosimetric and tumor control consequences of prostate seed loss and migration.

Authors:  Courtney Knaup; Panayiotis Mavroidis; Carlos Esquivel; Sotirios Stathakis; Gregory Swanson; Dimos Baltas; Nikos Papanikolaou
Journal:  Med Phys       Date:  2012-06       Impact factor: 4.071

4.  Evaluation of the dosimetric impact of loss and displacement of seeds in prostate low-dose-rate brachytherapy.

Authors:  Yinkun Wang; Nicola J Nasser; Jette Borg; Elantholi P Saibishkumar
Journal:  J Contemp Brachytherapy       Date:  2015-06-09

5.  Practical considerations in the selection of seed strength for prostate implants.

Authors:  Sarah L Elliott; Catherine L Beaufort; Jeremy L Millar
Journal:  J Appl Clin Med Phys       Date:  2015-09-08       Impact factor: 2.102

6.  CT-guided 125I interstitial brachytherapy for pelvic recurrent cervical carcinoma after radiotherapy.

Authors:  Lina Tong; Ping Liu; Bin Huo; Zhi Guo; Hong Ni
Journal:  Onco Targets Ther       Date:  2017-08-17       Impact factor: 4.147

7.  A novel three-dimensional template combined with MR-guided 125I brachytherapy for recurrent glioblastoma.

Authors:  Xiangmeng He; Ming Liu; Menglong Zhang; Roberto Blanco Sequeiros; Yujun Xu; Ligang Wang; Chao Liu; Qingwen Wang; Kai Zhang; Chengli Li
Journal:  Radiat Oncol       Date:  2020-06-08       Impact factor: 3.481

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.